Alzheimer Disease & Dementia

New data show APOE4 worsens early sleep disruption in Alzheimer models; CN-105 and zolpidem restore deep sleep and may slow amyloid buildup.

FDA grants Fast Track to Acadia’s remlifanserin for Alzheimer disease psychosis, targeting hallucinations and delusions as RADIANT trial advances toward 2026 data.

Oral THC/CBD combo rapidly eases severe dementia agitation in phase 2 trial, with sustained 12-week benefit and similar safety to placebo.

New review links lithium and Alzheimer disease treatment, fueling calls for biomarker-guided, low-dose clinical trials testing lithium’s multi-target disease-modifying potential.

New primate data show IV tau-silencing gene therapy cuts brain tau up to 75% with liver-sparing safety, clearing path for 2026 trial.

Phase 2 MINDFuL data show XPro trends toward cognitive and biomarker gains in inflammation-defined mild Alzheimer disease, with no ARIA, guiding phase 3 plans.

New psychiatry drugs target dementia agitation, ADHD, depression, TRD, and schizophrenia—see which novel mechanisms may reach the FDA next.

The FDA has approved Auvelity, an oral NMDA/sigma-1 therapy, offering a new option to curb Alzheimer disease agitation and ease caregiver burden.

AXS-05 for Alzheimer disease agitation nears FDA decision date.

Emerging student researchers share their award-winning neuroscience and psychiatry projects.

Data suggest PBFT02 therapy boosts progranulin and slows neurodegeneration markers in early FTD.

Experts share more on research developments of remternetug for Alzheimer disease.

Shared pathophysiology between Alzheimer disease and autism may expand diagnosis and treatment opportunities.

New data on long-term donanemab treatment.

Blood-based biomarkers for Alzheimer disease continue to improve, shares expert researcher.

AD/PD 2026 highlights oral blarcamesine preserving brain volume and IV lecanemab sustaining use while clearing amyloid-beta.

Early-life immigration may heighten dementia risk yet build resilience.

FDA reviews INmune Bio’s biomarker-enriched Phase 2b/3 plan for XPro1595.

Data and Safety Monitoring Board finds no safety issues for buntanetap at 6 months, keeping Annovis’ phase 3 early Alzheimer disease trial on track as enrollment progresses.

Cognition extends zervimesine expanded access for Lewy body dementia, adding months of dosing and easier local monitoring.

Research reveals links between gut microbiome composition and cognitive decline in Alzheimer disease and mild cognitive impairment.

New research reveals midlife ADHD patients exhibit early Alzheimer disease biomarkers.

Cassava Sciences shares insights from phase 3 trials of simufilam for Alzheimer disease, revealing potential treatment differences despite unmet primary endpoints.

Cognition Therapeutics shares zervimesine's promising phase 2 results, showing safety and improved symptoms in dementia with Lewy bodies.